Friday, 16 October 2026European Markets

TECHSTEP Stock 9.09% Up On Tuesday

Loading stream...

(VIANEWS) - The Market ended the session with TECHSTEP (TECH.OL) rising 9.09% to kr12.00 on Tuesday, after two consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI fell 0.37% to kr1,438.26, after two successive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

TECHSTEP's last close was kr11.00, 26.67% below its 52-week high of kr15.00.

About TECHSTEP

Techstep ASA operates as a mobile technology company in Norway, Sweden, Denmark, and Poland. The company offers device lifecycle management, mobile data capture, and mobile device management solutions; strategic and technical advisory services; and unified endpoint, endpoint, and application management services. It also provides mobile devices and accessories; and mobile management and security products. Techstep ASA was founded in 2016 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, TECHSTEP has a trailing twelve months EPS of kr-1.16.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -6.92%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 9%, now sitting on 1.06B for the twelve trailing months.

Volume

Today's last reported volume for TECHSTEP is 62853 which is 14.55% below its average volume of 73559.

Volatility

TECHSTEP's last week, last month's, and last quarter's current intraday variation average was a negative 2.22%, a negative 1.07%, and a positive 2.65%.

TECHSTEP's highest amplitude of average volatility was 3.51% (last week), 3.41% (last month), and 2.65% (last quarter).

Yearly Top and Bottom Value

TECHSTEP's stock is valued at kr12.00 at 22:30 EST, way below its 52-week high of kr15.00 and way higher than its 52-week low of kr7.45.

More news about TECHSTEP (TECH.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com